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Summary
We show in this study that endogenous NEP and PTEN associate in cells directly through electrostatic interactions between
a highly basic residue stretch in the intracellular domain of NEP and the major phosphorylation site in PTEN’s tail. NEP
binds and engages in higher order complexes both phosphorylated and unphosphorylated PTEN. NEP recruits PTEN to
the plasma membrane and enhances its stability and phosphatase activity. As a result, an enzymatically inactive NEP
mutant preserves the ability to bind PTEN, inactivates the Akt/PKB kinase, and partially suppresses the growth of PC cells.
This study demonstrates a molecular cooperation between NEP and PTEN tumor suppressors in which NEP constitutively
recruits and activates PTEN to inhibit the PI3K/Akt oncogenic pathway.
Introduction We have been investigating the role of NEP in prostate
cancer (PC), first reporting decreased NEP expression in andro-
Alterations in neuropeptide regulation contribute to the develop- gen-independent PC cells but not androgen-dependent LNCaP
ment and progression of prostate cancer (PC) (Hansson and cells and in tumor cells of metastatic PC tissue specimens from
Abrahamsson, 2001; Nelson and Carducci, 2000). Neuropep- patients with androgen-independent but not androgen-depen-
tides such as neurotensin, bombesin, and endothelin-1 (ET-1) dent PC (Papandreou et al., 1998). Lack of NEP expression
bind to G protein-coupled receptors (GPCR) and initiate signal- has also been observed in primary PCs (Chu and Arber, 2000;
ing pathways that stimulate cell growth (Rozengurt, 1998). Neu- Freedland et al., 2003). Together, these studies suggest that
tral endopeptidase 24.11 (NEP, neprilysin, CD10) is a 90–110 NEP loss may contribute to the development and progression
kDa zinc-dependent metallopeptidase that cleaves peptide of PC.
bonds on the amino side of hydrophobic amino acids and inacti- The biological and regulatory effects of NEP had been pre-
vates multiple physiologically active peptides, including bom-
sumed to result entirely from the catalytic inactivation of neuro-besin and ET-1 (Kenny, 1993; Shipp et al., 1991). NEP is a type
peptide substrates (Shipp and Look, 1993). Recently, however,II integral membrane protein, containing an inverted membrane
we have shown that NEP can regulate cell migration via mecha-orientation and possessing an extracellular carboxyl terminus
nisms both dependent and independent of its catalytic functionthat contains an active catalytic domain (Kenny, 1993). It is a
(Sumitomo et al., 2001). We also showed that catalytically activemember of the M13 family of zinc peptidases, which also in-
NEP inhibits neuropeptide-mediated activation of the insulincludes endothelin converting enzymes (ECE-1 and ECE-2),
growth factor-1 receptor (IGF-1R) and the resulting downstreamKELL, and PEX (see Turner et al., 2001, for review). A variety
activation of the PI-3 kinase and Akt/PKB kinase (Sumitomoof tissues normally express NEP, including prostatic epithelial
cells. et al., 2000). PI-3 kinase generates phosphatidylinositol-3,4,5-
S I G N I F I C A N C E
Neutral endopeptidase (NEP, CD10) is a cell surface enzyme expressed by prostatic epithelial cells that cleaves and inactivates
neuropeptides implicated in the growth of androgen-independent prostate cancer (PC). PTEN tumor suppressor, a lipid phosphatase
that antagonizes phosphatidylinositol 3-OH kinase (PI3K), is frequently inactivated in PC. Our study provides the first evidence of the
cooperation between NEP and PTEN tumor suppressors in the synergistic inhibition of the PI3K/Akt pathway in PC and opens the
perspective toward an altered regulation of wild-type PTEN that may be present in a large number of cancers. The novel plasma
membrane recruitment mechanism presented here demonstrates a long sought link between PTEN and its lipid substrates and may
provide the basis for a targeted cancer therapy.
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triphosphate (PIP3) by phosphorylating phosphatidylinositol- the two proteins (Figure 1A, top panel). Western blot analysis
with a PTEN antibody of proteins immunoprecipitated with an4,5-biphosphate (PIP2) (see Cantley and Neel, 1999, for review).
NEP antibody showed that PTEN co-immunoprecipitated withPIP3 is a second messenger that activates multiple downstream
NEP in MeWo melanoma cells that express both PTEN and NEPeffectors including Akt/PKB kinase, p70S6-kinase, Tec-family
proteins (Figure 1A, bottom panel). There was no complex for-tyrosine kinases, and the small G protein Rac. The Akt/PKB
mation in cells lacking either one of the two proteins, such asserine threonine kinase is a pivotal molecule for cancer progres-
LNCaP that do not express PTEN or TSU-Pr1 that lack NEP.sion that promotes cell growth, cell survival, and cell invasive-
The association between PTEN and NEP was confirmed by co-ness (for review see Hill and Hemmings, 2002).
immunoprecipitating NEP with a PTEN antibody (Figure 1A,PTEN phosphatase antagonizes the activity of PI-3 kinase
middle panel). These experiments showed that NEP and PTENby dephosphorylating PIP3 to PIP2 (Maehama and Dixon, 1998).
interact in vivo at endogenous protein expression levels.PTEN is a tumor suppressor frequently inactivated in a number
We next determined whether the catalytic activity of NEPof cancers including prostate, brain, and uterine cancer (Cairns
is necessary for the association with PTEN. NEP-deficient TSU-et al., 1997; Li et al., 1997; Steck et al., 1997; Tashiro et al.,
Pr1 PC cells were engineered to inducibly express upon tetracy-1997). Its inactivation in tumors results in increased activity of
cline removal wild-type NEP (WT-5 cells), catalytically inactiveAkt/PKB (Haas-Kogan et al., 1998). PTEN is a 403-residue pro-
NEP mutant (M-22 cells), truncated NEP mutant lacking its cyto-
tein structured in an amino (N)-terminal phosphatase domain
plasmic domain (CM-2 cells), or vector control (TN-12 cells).
and a carboxy (C)-terminal C2 domain that binds phospholipid PTEN co-immunoprecipitated with both wild-type and catalyti-
membranes (Lee et al., 1999). The unstructured C-terminal 50- cally inactive NEP, indicating that the interaction is independent
residue region (tail) contains two PEST sequences involved in of NEP’s peptidase activity (Figure 1B). PTEN did not associate
the stability of the molecule (Georgescu et al., 1999) and a PDZ with the CM-2 NEP mutant lacking the cytoplasmic domain,
(PSD95, Dlg, and ZO1) binding motif. The MAGUK adaptor-type implying that the cytoplasmic tail of NEP is necessary for binding
PDZ-domain proteins MAGI2 (Wu et al., 2000a), MAGI3 (Wu et PTEN.
al., 2000b), and hDLG (Huang et al., 2000) were reported to Because NEP co-immunoprecipitates with other molecules
interact via the C-terminal PDZ motif with PTEN. A major phos- (Ganju et al., 1996; Sumitomo et al., 2001), we examined whether
phorylation site has been mapped to residues S380, T382, and the interaction between NEP and PTEN is direct. NEP was im-
T383 in PTEN tail and shown to modulate the stability and munoprecipitated from cells and subjected to Far Western blot
activity of PTEN (Vazquez et al., 2000). If the function of PTEN analysis with a GST-PTEN probe (Figure 1C). GST-PTEN directly
as phosphoinositide phosphatase is well documented (see Mae- bound filter-immobilized NEP. This direct interaction took place
hama et al., 2001, for review), the regulation of its activity is still only when the cytoplasmic domain of NEP was intact, confirm-
ing that the interaction site with PTEN maps to the cytoplasmicpoorly understood.
domain of NEP.We report here that in addition to the catalytically dependent
mechanism of PI-3 kinase inactivation by cleavage of neuropep-
The major carboxy-terminal phosphorylationtides, NEP utilizes a catalytically independent mechanism that
site in PTEN binds to a basic-residue stretchinvolves the direct binding of NEP with the PTEN tumor suppres-
in the cytoplasmic domain of NEPsor. Mutagenesis studies mapped the site of interaction be-
To identify the region within PTEN that associated with thetween the two molecules to a positively charged amino acid
intracellular domain of NEP, we co-expressed NEP with a seriesstretch in the intracellular domain of NEP and the major phos-
of FLAG-tagged PTEN deletion mutants in 293T cells. Proteinsphorylation site in PTEN’s tail, thus defining a new modality of
from cell lysates were immunoprecipitated with NEP antibodyinteraction with PTEN. NEP recruits endogenous PTEN to the
and immunoblotted with M2 antibody that recognizes FLAG-membrane, leading to prolonged PTEN protein stability and
PTEN proteins (Figure 2A). NEP associated with full-lengthincreased PTEN phosphatase activity. This results in a constitu-
PTEN, with a truncation mutant lacking the amino terminustive downregulation of Akt/PKB activity and partial suppression
(C-term) and with the deletion mutants PTEN-385 and
of tumor growth for a catalytically inactive NEP mutant that
PTEN-398. NEP did not associate with PTEN-379 or with dele-
preserves the ability to bind PTEN. The importance of the coop-
tion mutants lacking carboxy-terminal residues upstream of
eration between PTEN and NEP for growth suppression was 379, indicating that the site of interaction between PTEN and
further confirmed in a panel of PC cell lines that consistently NEP maps to amino acids comprised between 379 to 385 in
showed disruption of the NEP-PTEN pathway. the carboxy-terminal region of PTEN. Surprisingly, this 6-residue
sequence contains a serine/threonine cluster (Ser380, Thr382,
Results Thr383, and Ser385) (Figure 2B) that represents the major phos-
phorylation site in PTEN (Vazquez et al., 2000). To analyze
NEP directly associates with the PTEN whether the interaction between PTEN and NEP depends on
tumor suppressor the phosphorylation status of PTEN, we immunoprecipitated
We previously reported that NEP indirectly inactivates Akt/PKB NEP from cell lysates treated with the serine/threonine phospha-
kinase by cleaving the neuropeptides bombesin and ET-1 (Sumi- tase PP2A (Figure 2C). A lower amount of PTEN associated
tomo et al., 2001). To determine whether NEP has a direct effect with NEP in cell lysates treated with PP2A than in cell lysates
on Akt/PKB, we investigated whether there is a link between left untreated, suggesting that NEP associates with both phos-
NEP and the PTEN tumor suppressor that converges to inacti- phorylated and unphosphorylated PTEN. To further assess the
vate Akt/PKB. We performed co-immunoprecipitation experi- importance of the phosphorylation sites for the interaction be-
tween NEP and PTEN, a triple PTEN-3A mutant, in whichments in cancer cell lines expressing different combinations of
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Figure 1. NEP protein co-immunoprecipitates
with PTEN protein
A: NEP (upper panel) and PTEN (middle panel)
immunoprecipitated with NEP and PTEN mAbs
were analyzed by Western blotting with NEP mAb
and PTEN pAb. Note NEP and PTEN co-immuno-
precipitate in Mewo melanoma cells that ex-
press endogenous NEP and PTEN. Mouse IgG was
used as negative control (Cont.) for immunopre-
cipitation. Lower panel shows Western blot of to-
tal cell lysates (TL) illustrating endogenous protein
levels of NEP and PTEN, with actin control.
B: WT-5, TN-12, M-22, and CM-2 tet-off inducible
cells were cultured with () and without () 1
g/ml tetracycline. Cell lysates were analyzed
as described in A. Note PTEN co-immunoprecipi-
tates with both wild-type (WT-5) and catalytically
inactive (M-22) NEP, but not with the NEP mutant
lacking the cytoplasmic domain (CM-2). TN-12
represents control cells containing identical vec-
tors lacking NEP cDNA.
C: WT-5, TN-12, and CM-2 cells were cultured with
() and without () tetracycline. NEP immuno-
precipitated with pAb were Far Western blot-
ted using GST-PTEN probe and anti-GST mAb (up-
per panel). GST-PTEN bound to NEP-expressing
LNCaP and Mewo, and wild-type NEP (WT-5) but
not cytoplasmic deleted NEP protein (CM-2). Re-
combinant GST protein (0.1 g) was used as a
positive control for anti-GST antibody, and the
PDZ domain from a protein isolated in yeast two-
hybrid screen (M.-M.G., unpublished data) as
positive control for GST-PTEN. Lower panel repre-
sents the same blot shown in upper panel
stripped and reprobed with anti-NEP mAb.
Ser380, Thr382, and Thr383 were changed to alanines (Figure form of the endogenous PTEN that associates with NEP, we
performed gel filtration over a Sephacryl S-300 column with2B), was co-expressed with NEP (Figure 2C). In this case, there
was no association between NEP and the phosphorylation- whole-cell lysates from TSU-WT-5 cells cultured in the presence
or in the absence of tetracycline (Figure 3A). Similarly to the ratdeficient PTEN-3A mutant. NEP’s ability to bind dephosphory-
lated PTEN but not the PTEN-3A mutant indicates that this liver cells, which have undetectable expression of NEP protein
binding is indeed restricted to the short sequence of the major (Ronco et al., 1988), in TSU-WT-5 cells not expressing NEP,
phosphorylation site whose integrity in terms of hydrophilicity PTEN eluted in two peaks: one at high molecular mass (669
and negative charge is necessary for NEP binding. kDa) and one corresponding to the monomeric form (apparent
The 6-residue stretch of PTEN responsible for the associa- molecular mass 67 kDa). When NEP was expressed in these
tion with NEP is a highly acidic sequence especially when phos- cells by tetracycline withdrawal, the 67 kDa form of PTEN shifted
phorylated (Figure 2B). The examination of the NEP cytoplasmic into a higher molecular weight complex of approximately 200
tail that is highly conserved across species revealed a motif of kDa apparent molecular mass. The apparent molecular mass
positively charged amino acids near the transmembrane domain of this complex corresponds roughly to the sum of the molecular
(Figure 2D). Mutagenesis of a cluster of three positively charged masses of PTEN and NEP, suggesting that the monomeric phos-
lysines within the cytoplasmic domain of NEP to glutamine, phorylated form of PTEN associated with NEP in cells. Interest-
asparagine, and isoleucine (QNI) blocked NEP’s association to ingly, the PTEN form present in high molecular weight com-
PTEN (Figure 2E). These experiments indicated that there is a plexes was also shifted upon NEP expression, suggestive of
direct association between PTEN and NEP based on electro- NEP participation in this complex also. Induced NEP eluted in
static interactions between a negatively charged phosphoryla- a plateau covering the monomeric to low order complexed forms
tion site in PTEN carboxyl terminus and a highly positively and a strong peak corresponding to the high order complex
charged site located in the cytoplasmic tail of NEP. (more than 669 kDa) in which dephosphorylated PTEN cofractio-
nated. Although induced NEP levels in TSU-WT-5 cells are com-
parable to endogenous levels, we also confirmed that the in-NEP associates with both phosphorylated
and unphosphorylated forms of PTEN duced NEP elution pattern was identical to the endogenous
NEP pattern from LNCaP cells (not shown).A previous study using gel filtration fractionation showed that
the unphosphorylated form of PTEN is present in rat liver cells To confirm that the data found by gel filtration experiments
indicating that both phosphorylated and unphosphorylatedin a high molecular weight complex while the phosphorylated
form is monomeric (Vazquez et al., 2001). To determine the forms of endogenous PTEN associate with NEP, we quantified
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Figure 2. A basic motif in NEP cytoplasmic domain binds to major phosphorylation site in PTEN’s tail
A: Cell lysates from 293T cells transiently co-expressing FLAG-tagged PTEN wild-type and mutants together with wild-type NEP protein were immunoprecipi-
tated with NEP mAb and immunoblotted with the M2 antibody recognizing FLAG-tagged proteins (upper panel) and NEP mAb (middle panel). Note that
PTEN and NEP co-immunoprecipitate only in cells expressing full-length PTEN protein or PTEN containing carboxy-terminal residues upstream of amino acid
379. The lower panel shows the expression level of the PTEN mutants in total lysates (TL) (50 g of protein) from transiently transfected 293T cells analyzed
by immunoblotting with the M2 antibody.
B: The PTEN sequence containing a serine/threonine cluster (Ser380, Thr382, Thr383, and Ser385) representing the major phosphorylation site in PTEN.
Underlined residues were changed to alanine in PTEN-3A mutant.
C: Identical experiment as in A using selected PTEN constructs and PTEN-3A mutant. Cell lysates were incubated with () or without () the serine/threonine
protein phosphatase PP2A. Note the lack of association between NEP and PTEN-3A mutant and the decreased association between NEP and PTEN proteins
from lysates treated with PP2A.
D: NEP cytoplasmic tail containing a highly conserved positively charged amino acid motif (in bold) near the transmembrane domain (underlined). The
lysine triplet mutated to QNI in the NEP-QNI mutant is boxed.
E: Cell lysates from 293T cells transiently transfected with vectors expressing wild-type () NEP or PTEN, and mutated PTEN-3A and NEP-QNI were immunoprecip-
itated with anti-NEP mAb and Western blotted with M2 recognizing FLAG-tagged PTEN and with NEP mAb. Negative control (Cont.) mouse IgG was used
for immunoprecipitation. The expression level from total cell lysates (TL) of the transfected proteins is shown in the lower panels. Note NEP and PTEN only
associate in cells expressing wild-type NEP and PTEN proteins.
the amount of phosphorylated PTEN that associated with immu- antibody recognizing total (both phosphorylated and unphos-
phorylated) PTEN. A lower amount of phosphorylated PTENnoprecipitated NEP relative to the amount of the respective
endogenous PTEN forms from the total cell lysates of TSU- (approximately 10% of phosphorylated PTEN input) than of total
PTEN (approximately 40% of total PTEN input) co-immunopre-WT-5 cells (Figure 3B). To this purpose, we probed the same
blot with an antibody specifically recognizing phosphorylated cipitated with NEP, indicating that both phosphorylated and
unphosphorylated forms of PTEN associate with NEP.PTEN on residues Ser380, Thr382, and Thr383, followed by an
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Figure 3. Both phosphorylated and dephosphorylated forms of PTEN interact with NEP
A: TSU-WT-5 cells cultured with () and without () tetracycline were fractionated on an S-300 gel filtration column and immunoblotted with anti-NEP
antibody, stripped, and reprobed with anti-PTEN antibody. Note the shift with the apparent molecular mass of NEP of both PTEN peaks, monomeric
phosphorylated and complexed dephosphorylated, in the presence of NEP.
B: Total cell lysates (TL) representing 10% of the input protein used for immunoprecipitation and NEP immunoprecipitates (IP) from TSU-WT-5 cells treated
as in A were analyzed by Western blotting with phospho(Ser380/Thr382/Thr383)-PTEN (P-PTEN), total PTEN, and NEP antibodies. Mouse IgG was used as
negative control for immunoprecipitation. The graph shows the quantification of the interaction between NEP and phosphorylated PTEN or total PTEN,
relative to the 10% input from total cell lysates.
NEP recruits PTEN to the plasma membrane and increases NEP-expressing cells is a consequence of reduced degradation,
we performed pulse-chase assays in WT-5 cells in the presenceits stability and phosphatase activity
NEP is a transmembrane molecule, localized at the plasma or in the absence of tetracycline (Figure 5B). The half-life of
PTEN was longer in induced NEP-positive WT-5 cells (T1/2  6membrane. To examine the consequence of NEP-PTEN associ-
ation on PTEN intracellular distribution, WT-5 and CM-2 cells hr) compared with noninduced NEP-negative WT-5 cells (T1/23
hr). These results suggested that in cells where PTEN associatesthat inducibly express full-length NEP or the cytoplasmic-
deleted NEP mutant, respectively, were labeled for immunoflu- with NEP, PTEN levels are increased by reduced degradation
of the protein.orescent analysis (Figure 4). In cells that did not express NEP
or that expressed the cytoplasmic-deleted NEP mutant that did To confirm that NEP controls the levels of PTEN in cells
that endogenously express both proteins, we depleted NEP bynot interact with PTEN, PTEN had a perinuclear intracellular
localization. Following expression of NEP, a fraction of PTEN introducing small interfering RNA (siRNA) for NEP into MEWO
melanoma cells (Figure 5C). NEP-specific enzyme activity con-was recruited at the plasma membrane, where it colocalized
with NEP (Figure 4). sistently decreased by 25% in MEWO NEP-siRNA-transfected
cells as compared to controls (data not shown). Western blotThe carboxy-terminal region of PTEN has been implicated
in the stability of the molecule (Georgescu et al., 1999). To analysis of MEWO cell lysates also showed an approximately
25% decrease in NEP protein levels in cells receiving siRNAexamine the possible impact of the NEP-PTEN association on
PTEN stability, we analyzed the protein expression level of PTEN (Figure 5C). In these cells, PTEN protein levels decreased more
than 30% as compared to controls, while there was no effectin cell lysates by using the inducible system of NEP expression
(Figure 5A). In WT-5 or M-22 cells that express NEP proteins on the amount of the -actin protein. These data indicated that
the loss of NEP in MEWO cells has a significant impact on PTENable to interact with PTEN, the expression levels of PTEN were
increased. In CM-2 cells that express the cytoplasmic-deleted levels.
Finally, to determine whether the stabilization and plasmaNEP mutant that does not interact with PTEN, PTEN levels were
unchanged. To determine if the increased stability of PTEN in membrane recruitment modified the enzymatic activity of PTEN,
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Figure 4. NEP recruits PTEN to the plasma mem-
brane
WT-5 cells stably expressing wild-type NEP and
CM-2 cells expressing cytoplasmic-deleted mu-
tant of NEP were cultured with () and without
() tetracycline and stained with anti-NEP anti-
body (upper panel) and anti-PTEN antibody
(lower panel). Note perinuclear intracellular lo-
calization of PTEN in cells lacking NEP (left) or full-
length NEP (right) in contrast to cells expressing
NEP (center) in which a fraction of PTEN was re-
cruited at the plasma membrane, where it colo-
calized with NEP (arrow).
an in vitro phosphatase assay was performed on PTEN immuno- dent mechanisms. The last mechanism most likely relies on the
direct interaction between NEP and PTEN, resulting in enhance-precipitated from cells expressing full-length or cytoplasmic-
deleted NEP mutant (Figure 5D). The lipid phosphatase activity ment of PTEN’s phosphatase activity.
We further investigated the molecular requirements for NEPof PTEN toward PIP3 was significantly increased in the presence
of full-length active or inactive NEP (WT-5 and M-22 cells), but growth suppression by testing the ability to suppress cell growth
of wild-type, catalytically inactive, and cytoplasmic domain mu-not in the presence of the cytoplasmic-deleted NEP mutant
(CM-2 cells) or in control TN-12 cells. These results showed tant NEP (Figure 6C). Both the catalytically inactive and the
cytoplasmic domain NEP mutants conferred intermediatethat in the presence of NEP, the phosphatase activity of PTEN
is increased. growth suppression to cells between that of wild-type NEP and
of vector control. These data were in correlation with the Akt/
PKB inactivation data and indicated that the growth suppressionThe NEP-PTEN cooperation is necessary for full
suppression of Akt/PKB activation and cell growth by NEP required both an intact extracellular peptidase activity
and the intracellular domain of NEP that recruits PTEN to thePTEN inactivates Akt/PKB by dephosphorylating PIP3 to PIP2
(Stambolic et al., 1998). Because the phosphatase activity of plasma membrane.
To confirm that the cooperation between NEP and PTEN isPTEN was increased in the presence of both catalytically active
and inactive NEP, we expected that catalytically inactive NEP important for PC cell growth, we analyzed the expression of
NEP and PTEN as well as the downstream activity of Akt/PKBwould also inactivate Akt/PKB through its direct interaction with
PTEN. To test this, we explored Akt/PKB phosphorylation by in four PC cancer cell lines (Figure 7). The melanoma cell line
Western blot analysis in cells induced to express wild-type or Mewo that expresses both NEP and PTEN was taken for com-
catalytically inactive NEP (Figure 6A). WT-5, TN-12, and M-22 parison. None of the PC cell lines expressed simultaneously
cells were cultured in serum-free media overnight, resulting in PTEN and NEP, suggesting that these molecules belong to
minimal levels of phosphorylated Akt/PKB (not shown) (Sumi- the same pathway. One cell line, PC-3, was deficient in both
tomo et al., 2000). Cells were then treated with 10 nM ET-1 for proteins. Akt/PKB was phosphorylated and thus activated in all
10 min, which induced Akt/PKB phosphorylation in cells lacking the PC cell lines, in spite of the presence of wild-type PTEN in
NEP expression (lanes 1, 2, 5, 6, and 7). Wild-type NEP inhibited two of them, TSU-Pr1 and DU145. However, the highest levels
Akt/PKB phosphorylation (lane 3). In the same conditions, the of Akt/PKB phosphorylation were observed in PC-3 cells that
catalytically inactive NEP mutant M-22 also inhibited Akt/PKB lacked both molecules and the lowest levels in Mewo cells
phosphorylation, although not completely (lane 8). Similarly, that expressed both molecules. These observations are highly
treatment of cells expressing wild-type NEP with CGS24592 suggestive for synergy between NEP and PTEN for the full sup-
NEP-specific peptidase inhibitor failed to restore the complete pression of Akt/PKB activity in cancer cells.
activation of Akt/PKB (lane 4). To assess the influence of NEP
on Akt/PKB activity in the presence of a PI-3 kinase agonist Discussion
that is not susceptible to degradation by NEP, we performed
similar experiments using IGF-1 (1 ng/ml). Expression of NEP PTEN is an important tumor suppressor whose inactivation fre-
quency in cancers is ranked second after p53 tumor suppressorin WT-5 and M-22 cells similarly inhibited Akt/PKB phosphoryla-
tion, whereas no effect was seen in CM-2 cells that express NEP inactivation (Cantley and Neel, 1999). Increasing evidence sug-
gests that NEP peptidase can function as a tumor suppressor.lacking the cytoplasmic domain (Figure 6B). These experiments
indicated that NEP is able to inactivate Akt/PKB through both Loss of NEP expression has been reported in a variety of solid
tumors (Nanus et al., 1997). More specifically, NEP expression isindirect catalytically dependent and direct catalytically indepen-
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Figure 5. NEP stabilizes PTEN protein expression and increases PTEN lipid phosphatase activity
A: PTEN protein expression levels were determined by Western analysis using a PTEN mAb in cell lysates from WT-5, TN-12, M-22, and CM-2 cells in the
presence () or absence () of tetracycline. Note increased PTEN protein in cells expressing NEP protein containing intact cytoplasmic domain in contrast
to empty-vector control cells (TN-12) or to cells expressing the cytoplasmic-deleted NEP mutant (CM-2).
B: The turnover of PTEN was evaluated by pulse-chase assay as described in Experimental Procedures. The half-life of PTEN was prolonged in NEP-positive
WT-5 cells under tetracycline-free (Tet) medium compared with WT-5 cells cultured in the presence of tetracycline (Tet) that suppresses NEP expression.
The relative intensity of each band obtained by autoradiography was measured by ImageJ software and represented in the graph.
C: Partial NEP gene silencing analysis shows decrease in endogenous PTEN protein levels in MEWO cells treated with lipofectamine and NEP siRNA in
comparison with control cells treated with lipofectamine alone (lipo). No effect was noted on -actin protein. These data are representative of multiple
independent experiments.
D: In vitro phosphatase assay on PTEN immunoprecipitated from WT-5, TN-12, M-22, and CM-2 cells in the presence and absence of tetracycline (tet). Bars
represent standard deviations from triplicate measurements. Note significant increase in PTEN lipid phosphatase activity in cells expressing intact NEP
cytoplasmic domain following tetracycline removal compared to control TN-12 or cytoplasmic-deleted NEP mutant CM-2.
diminished in a significant percentage of primary and metastatic tomo et al., 2000), or induces ligand-independent activation of
IGF-1R and subsequent Akt/PKB activation that regulates cellPCs (Chu and Arber, 2000; Papandreou et al., 1998; and our
unpublished data), most likely by reduced transcription (Dhana- growth (Sumitomo et al., 2001). A second mechanism consists
of the direct association between NEP and Lyn kinase, whichsekaran et al., 2001). Reduction in NEP activity in lung cancer
cells has been directly implicated in the development of lung recruits the p85 regulatory subunit of PI-3 kinase and competi-
tively blocks the interaction of the PI-3 kinase with FAK, leadingcancer (Bunn et al., 1998; Cohen et al., 1996; Shipp et al., 1991).
The mechanism by which the loss of NEP contributed to tumor to decreased cell migration (Sumitomo et al., 2000). In the cur-
rent study, we have identified a third mechanism of NEP antitu-progression was believed to rely solely on the inability of the
cell to inactivate mitogenic peptides (Shipp and Look, 1993). mor action by its direct association with the PTEN tumor sup-
pressor. NEP recruits PTEN to the plasma membrane andOur recent work including the data from this study demonstrated
that both the catalytic function and the ability of the intracellular increases its stability and phosphatase activity. Functionally,
this results in the inactivation of Akt/PKB and growth suppres-domain of NEP to participate to protein complexes are required
for tumor growth suppression (Figure 8). We previously identified sion by a catalytically inactive mutant of NEP that preserves its
ability to bind PTEN.two distinct mechanisms by which NEP exerts a tumor-sup-
pressive effect. A first mechanism consists of the catalytic inacti- The association between NEP and PTEN opens new insights
for PTEN regulation, an area where little is known. PTEN functionvation of neuropeptide substrates that signal through G protein-
coupled receptors to activate Src kinase (Sumitomo et al., 2000). is to inactivate the PI-3 kinase pathway. This pathway is active,
as measured by Akt/PKB activity and/or phosphorylation, inSrc directly activates FAK, which regulates cell migration (Sumi-
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Figure 7. Synergy between NEP and PTEN for Akt/PKB inactivation in PC cell
lines
Equal numbers of PC cells grown in medium supplemented with 10% FCS
were lysed, and 50 g proteins from total lysates were analyzed by Western
blot with the indicated antibodies. The graph shows the level of phosphory-
lated Akt/PKB normalized to the total Akt/PKB level. Note highest or lowest
levels of phospho-Akt in cells that lack or express both NEP and PTEN mole-
cules, respectively.
tumors or cancer cell lines lacking PTEN (Haas-Kogan et al.,
1998). However, we observed in this study that there is moderate
Akt/PKB activation in some cancer cell lines that expressed
wild-type PTEN but lacked NEP. Our interpretation is that in
these cancer cell lines that lack NEP, the regulation of PTEN is
impaired. This assumption is based on the data showing clear
alteration of PTEN expression levels after partial gene silencing
of NEP by siRNA in cells expressing both proteins. Moreover,
the induced expression of NEP in one of the NEP-deficient
Figure 6. Catalytically inactive NEP partially inactivates Akt/PKB and tumor cell lines regulated PTEN’s activity by multiple mechanisms,
growth resulting in a constitutive activation of PTEN that increased
A: WT-5, TN-12, and M-22 cells were cultured overnight in serum-free media significantly the threshold for Akt/PKB activation by neuropep-
in the presence () or absence () of tetracycline. 10 nM ET-1 was added
tides and growth factors. The mobilization of monomeric PTENfor 10 min prior to cell lysis. Cell lysates were Western blotted with pAbs to
in complexes, as shown by gel filtration experiments, may havephospho-Akt (P-Akt) and total Akt. Where indicated, cells were also treated
with 10 nM of the NEP enzymatic inhibitor CGS24592 for 2 hr prior to treatment increased the stability of PTEN. The recruitment of PTEN to the
with ET-1. Note the decrease in phospho-Akt in both M-22 cells expressing cell membrane from a perinuclear pool most likely played an
catalytically inactive full-length NEP and in WT-5 cells expressing wild-type important role in PTEN’s activation, and we have previouslyNEP that had its catalytic activity inhibited by CGS24592.
shown that the artificial targeting of PTEN to the membraneB: WT-5, TN-12, M-22, and CM-2 cells were cultured as indicated in A and
treated with 1 ng/ml of IGF-1, which is not a substrate for NEP. Note the increases its tumor suppressor function (Georgescu et al., 2000).
comparable decrease in phospho-Akt in both WT-5 and M-22 cells express- Recent studies have shown by density gradient centrifugation
ing full-length wild-type or catalytically inactive NEP, respectively, but not that both NEP and PTEN partly cofractionated with caveolin-
in CM-2 cells expressing NEP lacking the cytoplasmic domain.
1-enriched membrane microdomains or rafts (Caselli et al.,C: Equal numbers of WT-5, TN-12, M-22, and CM-2 Tet-off inducible cells
2002; Riemann et al., 2001). Moreover, both caveolin, the mainwere plated and grown in medium supplemented with 10% FCS with ()
or without () tetracycline (Tet.). After 5 days, the number of cells was structural protein of rafts, and cholesterol that is enriched in
counted. All experiments were performed in triplicate and error bars repre- rafts were functionally associated with PC progression (Tahir et
sent standard errors. p values estimate differences between cells grown al., 2001; Zhuang et al., 2002). As the membrane distributionwith and without tetracycline: WT-5 cells, p  0.0062; M-22 cells, p  0.0193;
of PTEN appears crucial for PTEN’s regulation, we are currentlyCM-2 cells, p  0.0421. The presented data are representative of two inde-
pendent experiments with similar results. investigating whether caveolin-1 is present in the NEP-PTEN
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Figure 8. Mechanistic model of NEP’s inhibition
of cell growth and migration
NEP has at least three independent regulatory
functions that can affect PC cells: (1) NEP cata-
lytically inactivates a variety of neuropeptide
substrates such as bombesin and ET-1, thereby
blocking neuropeptide actions, including Src
phosphorylation and association with FAK, nor-
mally resulting in cell migration, and neuropep-
tide-mediated ligand-independent activation of
growth factor (GF) receptors such as IGF-IR; (2)
NEP indirectly associates with p85 regulatory sub-
unit of the PI-3 kinase through Lyn kinase, thereby
inhibiting the interaction of PI-3 kinase with FAK;
and (3) NEP directly associates with and stabilizes
PTEN tumor suppressor, leading to dephosphory-
lation of PIP3 to its less active form, and resulting
in negative regulation of downstream cell
growth and cell survival pathways such as those
regulated by Akt/PKB kinase.
gel filtration peaks in order to define what form of PTEN coloca- on NEP function are unknown. CK2 is elevated in proliferating
and neoplastic tissues (Pinna, 1997), and conceivably CK2 maylized with NEP at the plasma membrane.
A very remarkable finding was the critical localization of the regulate the interaction of PTEN and NEP through phosphory-
lation.binding sites on PTEN and NEP. These sites likely mediate an
electrostatic interaction between the two molecules and consist We have shown here that NEP and PTEN are on the same
pathway for PC growth suppression. However, PTEN has beenof well-defined motifs limited to very short amino acid se-
quences. We could disrupt the reciprocal interaction by chang- implicated in a large array of cancers and noticeably, tumors
in which PTEN is frequently inactivated arise in tissues withing as few as three residues within each motif. This finding has
prompted us to perform database searches for detecting these highest expression of NEP (Ronco et al., 1988). In addition to PC,
a striking example where both NEP and PTEN are inactivated inmotifs in other proteins that may associate with either NEP or
PTEN and potentially modulate the NEP-PTEN interaction. a high percentage of cases is small cell lung cancer (Shipp et
al., 1991; Yokomizo et al., 1998), and it would be of considerableMost interestingly, the NEP-interacting motif on PTEN su-
perposes with the major phosphorylation site in PTEN (illus- importance to characterize the NEP-PTEN pathway in this set-
ting as well. Our study provides the first evidence of the coopera-trated in Figure 2B). PTEN’s phosphorylation at this site in-
creases the stability but decreases PTEN’s activity (Vazquez et tion between NEP and PTEN tumor suppressors in PC and
opens the perspective toward an altered regulation of wild-typeal., 2000) and the interaction of the neighboring PDZ binding
PTEN that may be present in a large number of cancers.motif with proteins from the MAGUK family (Tolkacheva et al.,
2001; Vazquez et al., 2001). We showed that the phosphoryla-
Experimental procedurestion regulates the interaction between PTEN and NEP as well,
but in a different manner compared with the MAGUK proteins.
Cell culture
As long as the major phosphorylation site was intact, both phos- LNCaP, TSU-Pr1, DU145, PC-3 PC, and 293T cells were maintained as
phorylated and unphosphorylated forms of PTEN bound to NEP. described (Georgescu et al., 1999; Sumitomo et al., 2000). Mewo melanoma
It thus appears that the phosphorylated form of PTEN may not cells were maintained in modified Eagle’s medium containing 10% FCS.
TSUGK27 is a TSU-Pr1 cell line stably transfected with pGK hygro andnecessarily be the inactive PTEN form but, in certain circum-
PUHD 15-1 containing the coding sequence for the tet repressor adjacentstances, it may be physiologically active. Recent studies indi-
to the coding sequence for the C-terminal domain of VP16 (named thecate that protein kinase CK2 (formerly casein kinase II) catalyzes
tet-responsible transactivator or tTA), downstream of the hCMV promoter
phosphorylation of PTEN (Miller et al., 2002; Torres and Pulido, (Gschwend et al., 1997). This cell line was cultured in media containing 150
2001). The NEP cytoplasmic tail contains two consensus recog- g/ml of hygromycin and 1 g/ml of tetracycline. Reagents used include
nition sequences for CK2, and similar to PTEN, NEP is phos- protein phosphatase 2A1 (PP2A) (Calbiochem-Novabiochem Ltd., La Jolla,
CA) and CGS24592 NEP competitive inhibitor (Novartis Pharmaceutical).phorylated by CK2 (Ganju et al., 1996). While phosphorylation
The following antibodies were used: mouse monoclonals (mAbs) to NEPof PTEN by CK2 is believed to inhibit PTEN function (Miller et
(J5, Beckman Coulter, Fullerton, CA; NCL-CD10-270, Novocastra Labora-al., 2002; Torres and Pulido, 2001), these studies on PTEN have
tories Ltd., Newcastle upon Tyne, UK; FR4D11, Santa Cruz Biotechnology,been performed in cell lines lacking NEP expression such as
Inc., Santa Cruz, CA), to PTEN (A2B1, Chemicon, International, Inc., Teme-
U87-MG glioblastoma cells. Our studies suggest that NEP also cula, CA), and to FLAG-tag (M2, Sigma-Aldrich, St. Louis, MO); rabbit poly-
associates with the phosphorylated PTEN when expressed clonals (pAbs) to NEP (5B5, Arris Pharmaceutical Corp., San Francisco, CA),
to PTEN (FL-403, Santa Cruz; Anti-PTEN, Upstate Biotechnology, Inc., Lakewithin the same cell. The effects of CK2 phosphorylation of NEP
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Placid, NY), to Akt (H-136, Santa Cruz), to phospho(Ser380/Thr382/Thr383)- Pulse-chase assay
Equal number of cells were cultured in RPMI1640 lacking methionine for 30PTEN and phospho(Ser473)-Akt (Cell Signaling Technology, Inc., Beverly,
min, in the same media containing 300 Ci/ml [35S]methionine (NEN) for 1MA), and to actin (Chemicon).
hr, washed with PBS, and then incubated in RPMI supplemented with 10%
FCS and 0.15 mg/ml nonradioactive methionine for various time periods.Plasmid construction and gene transfer
Cells were lysed in RIPA buffer. For immunoprecipitation, 300 g proteinsNEP wild-type TSU-GK27-NEP (WT-5), control TSU-GK27-Neo (TN-12), and
from lysates were incubated for 1 hr with 1 g of anti-PTEN antibody,catalytically inactive NEP TSU-GK27-mNEP (M-22) cells were generated and
then for 1 hr with 40 l protein G-sepharose beads (Amersham) at 4C.maintained as previously described (Dai et al., 2001; Sumitomo et al., 2000).
Immunoprecipitates were collected by centrifugation at 6000  g for 1 min,NEP cytoplasmic domain deletion mutant (pTRE/NEPdcyto) was constructed
washed with RIPA buffer, and resuspended in 2 Laemmli sample buffer.by site-directed mutagenesis (QuickChange; Strategene, La Jolla, CA) and
Samples were resolved on an 8% SDS-PAGE and transferred to nitrocellu-used to generate inducible TSU-GK27-CM cells (CM-2). The K12KK14 to QNI
lose. Autoradiography and immunoblotting were performed using the samemutant (pTRE/NEPQNI) in the NEP cytoplasmic domain was obtained by
membrane. The relative intensity of each band obtained by autoradiographyPCR-based site-directed mutagenesis using a set of primer including point
was measured by ImageJ software.mutations (underlined) as follows: 5	-CT GAT ATC AAC ACT CCA AAG CCA
CAG AAC ATA CAG CGA TGG ACT CCA CTG GAG-3	 and 5	-CTC CAG
PTEN phosphatase assayTGG AGT CCA TCG CTG TAT GTT CTG TGG CTT TGG AGT GTT GAT ATC
PTEN phosphatase assays were performed as described (Georgescu et al.,AG-3	. This mutant was used to generate inducible TSU-GK27-QNI cells
1999). The release of phosphate from the water-soluble diC8-PIP3 substrate(QNI-12) (Papandreou et al., 1998). Mutant NEP-QNI cDNA was also cloned
(Echelon) was measured in a colorimetric assay by using 100 l Malachitein pCISChENK vector for transient expression. N terminus FLAG-tagged
Green solution (Upstate) in accordance with the instructions of the manufac-PTEN wild-type and C-terminal deletion mutants ending at codons 254, 351,
turer. Data are representative of one experiment performed in triplicate on363, 379, 385, and 398 were previously described (Georgescu et al., 1999).
at least two separate occasions.The truncation mutant starting at amino acid 201 and conserving the C
terminus of PTEN (C-term) and the PTEN phosphorylation mutant disrupting
NEP siRNA assaythe major phosphorylation site by changing Ser380, Thr382, and Thr383 to
Mewo cells were plated at a concentration of 3  105 cells/ml in 6-wellalanines (PTEN-3A) were similarly cloned in pFLAG-CMV-2 vector.
plates (2 ml/well) and were transfected the following day with 300 pmol/well
of NEP siRNA (smartpool from Dharmacon Research, Inc., Lafayette, CO)Protein extraction, immunoprecipitation,
using lipofectamine Reagent (Invitrogen, Carlsbad, CA) according to theand Western blot analysis
manufacturer’s instructions. 72 hours after transfection, cells were harvestedCells were lysed in 1 ml of RIPA buffer (10 mM Tris-HCl [pH 7.4], 150 mM
and lysed in cold 0.1% CHAPS buffer (10 mM HEPES [pH 7.4], 5 mM DTT,NaCl, 1% Triton X-100, 5 mM EDTA, 1% sodium deoxycholate, 0.1% SDS,
2 mM EDTA), supplemented with protease inhibitors. Equal amounts of total1.2% aprotinin, 5 M leupeptin, 4 M antipain, 1 mM phenylmethylsulfonyl
protein (20 g) were separated on 8% polyacrylamide gels and transferredfluoride, 0.1 mM Na3VO4), and 300–500 g proteins were incubated 1 hr to
to nitrocellulose membrane. Western blotting was performed using antibod-overnight with 1–4 g primary antibody, and then for 1 hr with 40 l protein
ies to NEP (NCL-CD10-270), PTEN (A2B1), and actin.G-sepharose beads (Amersham Pharmacia Biotech, Piscataway, NJ) at 4C.
Immunoprecipitates were washed with RIPA buffer, resuspended in 2
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